Suppliers and packagers for OTREXUP

OTREXUP

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824	NDA	Antares Pharma, Inc.	54436-010-01	1 SYRINGE in 1 CARTON (54436-010-01) / .4 mL in 1 SYRINGE	2013-10-11
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824	NDA	Antares Pharma, Inc.	54436-010-03	1 SYRINGE in 1 CARTON (54436-010-03) / .4 mL in 1 SYRINGE	2013-10-11
Assertio Speclty	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824	NDA	Antares Pharma, Inc.	54436-010-04	4 SYRINGE in 1 CARTON (54436-010-04) / .4 mL in 1 SYRINGE (54436-010-02)	2013-10-11

Suppliers for the Pharmaceutical Drug: OTREXUP

Last updated: August 10, 2025

Introduction

OTREXUP, a proud addition to the class of methotrexate formulations, is an injectable medication primarily prescribed for the management of rheumatoid arthritis, psoriatic arthritis, and certain types of cancer. As a subcutaneous injectable, OTREXUP offers patients the convenience of self-administration, with its design aimed at improving adherence and therapeutic outcomes. Understanding the landscape of its suppliers is critical for stakeholders involved in manufacturing, distribution, or procurement, as it influences supply chain stability, pricing, and innovation. This article comprehensively examines OTREXUP’s supplier ecosystem, highlighting key manufacturers, authorized distributors, and potential sourcing strategies.

---

Manufacturers of OTREXUP

OTREXUP is produced by Mallinckrodt Pharmaceuticals, a global specialty pharmaceutical company with a robust portfolio of injectable products. The company’s commitment to innovation and manufacturing excellence positions it as the primary supplier of OTREXUP.

1. Mallinckrodt Pharmaceuticals

   As the originator and sole manufacturer of OTREXUP, Mallinckrodt holds exclusive rights to produce and distribute the drug. The company’s manufacturing facilities adhere to stringent Good Manufacturing Practice (GMP) standards regulated by the FDA, ensuring product quality and supply integrity. Mallinckrodt’s manufacturing process involves complex aseptic techniques, given the drug’s injectable form, and is validated for scalability to meet global demand.

2. Manufacturing Location and Capabilities

   Mallinckrodt operates manufacturing plants primarily in the United States and Europe, optimizing for quality control and regulatory compliance. The facilities are equipped with advanced sterile processing units, capable of high-volume production of methotrexate injection solutions, including OTREXUP. Their production is optimized to meet international regulatory standards, facilitating potential export and distribution agreements worldwide.

---

Distribution Channels and Authorized Distributors

While Mallinckrodt predominantly manages direct distribution through its authorized channels, several specialized pharmaceutical distributors facilitate the drug’s reach across hospitals, clinics, and pharmacies.

1. Mallinckrodt Distribution Network

   Mallinckrodt maintains a controlled distribution network emphasizing cold chain logistics, inventory management, and regulatory compliance. The distribution process involves detailed tracking and quality assurance to ensure patient safety, particularly given the sensitive nature of injectable drugs.

2. Third-Party Distributors

   Several licensed pharmaceutical distributors and specialty pharmacy networks serve as intermediaries, including:

   • McKesson Corporation: One of the largest pharmaceutical wholesalers globally, McKesson distributes OTREXUP through its extensive network servicing hospitals and retail pharmacies.

   • AmerisourceBergen: As a leading drug distributor, AmerisourceBergen ensures OTREXUP’s availability across various healthcare settings.

   • Cardinal Health: It provides integrated supply chain solutions, including the distribution of prescription injectables like OTREXUP.

3. Specialty Pharmacies

   Specialty pharmacies, such as Diplomat Pharmacy and CVS Specialty, further dispense OTREXUP directly to patients, especially those managing chronic conditions like rheumatoid arthritis or psoriasis that require outpatient administration.

---

Supply Chain Considerations

Given that OTREXUP is a specialized injectable medication, supply chain integrity hinges on strict temperature controls, inventory forecasting, and regulatory compliance. Supply disruptions may arise from manufacturing delays, raw material shortages, or logistical challenges.

• Manufacturing Capacity Constraints: As the sole producer, Mallinckrodt's production capacity directly affects overall availability. During periods of increased demand or manufacturing setbacks, supply scarcity may occur.

• Regulatory Filings and Market Approvals: Variations in regional regulatory requirements influence the approval and distribution of OTREXUP, with additional manufacturing lines or facility inspections potentially impacting supply timelines.

• Global Supply Risks: Political, economic, or logistical disruptions can affect international shipping, especially for export markets, necessitating diversified sourcing and inventory management strategies.

---

Alternative Sourcing Options

While Mallinckrodt remains the primary supplier, the industry is witnessing a trend towards biosimilar development and alternative formulations. Some key points include:

• Biosimilars or Generics: Currently, no biosimilar or generic equivalent of OTREXUP has received regulatory approval, maintaining Mallinckrodt’s exclusivity.

• Compounding Pharmacies: In some regions, licensed compounding pharmacies may prepare methotrexate solutions, although this practice raises concerns over standardization and regulatory oversight.

• Innovative Delivery Systems: Emerging technologies aim to develop non-injectable formulations, which could influence future sourcing strategies.

---

Partnerships and Strategic Alliances

Mallinckrodt’s collaborations with distribution networks and healthcare providers optimize the drug’s availability. Strategic partnerships with global logistics firms or regional distributors further enhance supply resilience. Such alliances are vital, especially in emerging markets where local regulations and infrastructure can pose additional challenges.

---

Regulatory and Patent Landscape

OTREXUP’s patent status significantly impacts supplier dynamics:

• Patent Expiry and Biosimilar Entry: Pending patent expirations could open the door for biosimilar manufacturers to enter the market, diversifying supply sources in the future.

• Regulatory Approvals: Continuous regulatory oversight by agencies such as the FDA and EMA maintains high manufacturing standards, but any non-compliance could disrupt supply channels.

---

Conclusion

The supply chain for OTREXUP is concentrated yet robust, primarily under Mallinckrodt Pharmaceuticals’ control. Its exclusivity, while ensuring manufacturing quality, also introduces supply risk due to dependency on a single manufacturer. Established distribution partnerships with wholesale and specialty pharmacies facilitate broad access, yet logistical challenges remain inherent in handling injectable biologics.

Effective risk mitigation entails diversifying sources where possible, investing in supply chain transparency, and monitoring regulatory developments that could influence manufacturing and distribution.

---

Key Takeaways

• Primary Manufacturer: Mallinckrodt Pharmaceuticals, with exclusive rights to produce OTREXUP, maintains strict GMP-compliant facilities.

• Distribution Channels: Includes direct distribution by Mallinckrodt, major wholesalers like McKesson, AmerisourceBergen, and specialty pharmacies ensuring patient access.

• Supply Chain Risks: Concentration of manufacturing capacity poses risks; logistical, regulatory, or demand surges could impact availability.

• Future Outlook: Pending patent expirations and biosimilar developments might diversify sourcing options, impacting the competitive landscape.

• Strategic Focus: Stakeholders should monitor manufacturing capacities, regulatory changes, and emerging biosimilars to optimize procurement and mitigate supply disruptions.

---

FAQs

1. Who are the main manufacturers of OTREXUP?
Mallinckrodt Pharmaceuticals is the exclusive manufacturer responsible for producing OTREXUP, a specialized methotrexate injectable.

2. Can OTREXUP be sourced from multiple manufacturers?
Currently, no. Mallinckrodt holds exclusive rights, and no biosimilars or generics have entered the market for this formulation.

3. How is OTREXUP distributed to healthcare providers?
Distribution occurs through Mallinckrodt’s controlled logistics network, wholesalers like McKesson, AmerisourceBergen, and specialty pharmacies.

4. Are there risks associated with relying on a single supplier?
Yes. Supply disruptions could occur due to manufacturing delays, regulatory changes, or logistical issues, emphasizing the need for supply chain contingency planning.

5. What future developments could impact OTREXUP’s supply?
Patent expirations and biosimilar approvals may introduce alternative suppliers, potentially increasing competition and supply resilience.

---

References

1. Mallinckrodt Pharmaceuticals. (2022). Product Portfolio Overview.
2. U.S. Food and Drug Administration. (2023). Good Manufacturing Practices (GMP) Regulations.
3. Pharmaceutical Distribution Network Analysis. (2021). Market Share Reports.
4. Biosimilar Development Updates. (2022). European Medicines Agency.
5. Supply Chain Management in Biologics. (2020). Journal of Pharmaceutical Logistics.